edicotinib   Click here for help

GtoPdb Ligand ID: 8942

Synonyms: JNJ-40346527 | JNJ40346527 | US8497376, 15
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Edicotinib (PRV-6527; previously JNJ-40346527) was identified in a medicinal-chemistry lead optimization study to develop oral, selective CSF1R kinase inhibitors. The chemical structure is compound I-S in patent US20140045789 [2]. PubChem CID 25230468 is a tautomer which is also claimed in the patent.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 103.69
Molecular weight 461.28
XLogP 4.84
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#Cc1c[nH]c(n1)C(=O)Nc1ccc(nc1C1=CCC(CC1)(C)C)C1CC(C)(C)OC(C1)(C)C
Isomeric SMILES N#Cc1c[nH]c(n1)C(=O)Nc1ccc(nc1C1=CCC(CC1)(C)C)C1CC(C)(C)OC(C1)(C)C
InChI InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)
1. Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan XD, Ge T, Franks C et al.. (2015)
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
J Rheumatol, 42 (10): 1752-60. [PMID:26233509]
2. Kolodziejczyk K, Stappers AE, Teleha CA, Weerts KJH. (2014)
Process for the preparation of c-fms kinase inhibitors.
Patent number: US20140045789 A1. Assignee: Janssen Pharmaceutica Nv.. Priority date: 07/08/2012. Publication date: 13/02/2014.